CRNX · Crinetics Pharmaceuticals, Inc.
$83.90
+0.03 (+0.04%)
At close · Jul 21
Market Cap
$8.85B
Shares
105.44M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$7.7M
+640.7%
FY2025
Net Income
-$465.32M
-55.9%
FY2025
Gross Margin
86.02%
-14pp
FY2025
Operating Margin
-6714.77%
+25898.7pp
FY2025
Diluted EPS
-$4.95
-34.1%
FY2025
Operating Cash Flow
-$377.92M
-64.2%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $18.07M | $7.7M | $1.04M | $4.01M | $4.74M | $1.08M | $71K | $1.19M | $2.43M | $2.05M | $589K | |
| — | $1.08M | $0 | $0 | — | — | — | — | — | — | — | |
| — | $6.62M | $1.04M | $4.01M | — | — | — | — | — | — | — | |
| — | 86.02% | 100% | 100% | — | — | — | — | — | — | — | |
| $355.9M | $332.06M | $240.16M | $168.53M | $130.23M | $84.26M | $57M | $41.51M | $24.48M | $9.23M | $5.1M | |
| — | — | $99.74M | $58.09M | $42.39M | $24.53M | $18.03M | $13.52M | $6.66M | $1.94M | $1.53M | |
| — | $191.33M | $99.74M | $58.09M | — | — | — | — | — | — | — | |
| — | $3.9M | $2.8M | $1.1M | $983K | $922K | $948K | $887K | $471K | $128K | $92K | |
| $479.38M | — | $339.89M | $226.62M | $172.62M | $108.78M | $75.02M | $55.03M | $31.14M | $11.17M | $6.63M | |
| — | $524.47M | $339.89M | $226.62M | — | — | — | — | — | — | — | |
| -$545.74M | -$516.77M | -$338.85M | -$222.61M | -$167.88M | -$107.7M | -$74.95M | -$53.83M | -$28.71M | -$9.13M | -$6.04M | |
| — | -6714.77% | -32613.47% | -5547.17% | -3544.06% | -9990.91% | -105567.61% | -4512.32% | -1182.45% | -446.31% | -1026.15% | |
| — | -$512.87M | -$336.05M | -$221.51M | -$166.9M | -$106.78M | -$74.01M | -$52.95M | -$28.24M | -$9M | -$5.95M | |
| — | — | — | — | — | — | — | — | — | $8000 | $11K | |
| $49.82M | $51.99M | $41.44M | $13.44M | $4.32M | $157K | $991K | $3.46M | $1.75M | $26K | $37K | |
| $49.53M | $51.63M | $40.92M | $13.28M | $4.97M | $61K | $1.14M | $3.41M | $1.6M | -$30K | $25K | |
| — | $0 | -$470K | -$5.2M | — | — | — | — | — | — | — | |
| — | -$465.14M | -$298.41M | -$214.53M | -$163.92M | -$107.64M | -$73.81M | -$50.42M | -$27.12M | -$9.16M | -$6.02M | |
| — | $180K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| -$496.39M | -$465.32M | -$298.41M | -$214.53M | -$163.92M | -$107.64M | -$73.81M | -$50.42M | -$27.12M | -$9.16M | -$6.02M | |
| — | -6046.22% | -28720.69% | -5345.85% | -3460.38% | -9985.25% | -103960.56% | -4226.49% | -1116.76% | -447.78% | -1021.9% | |
| -$499.64M | -$464.42M | -$298.42M | -$209.62M | -$167.47M | -$108.05M | -$73.94M | -$50.34M | -$27.05M | -$9.16M | -$6.02M | |
| USD/shares | — | -$4.95 | -$3.69 | -$3.69 | -$3.15 | -$2.80 | -$2.42 | — | — | — | — |
| USD/shares | — | -$4.95 | -$3.69 | -$3.69 | -$3.15 | -$2.80 | -$2.42 | — | — | — | — |
| shares | — | 94.06M | 80.78M | 58.07M | 51.98M | 38.44M | 30.45M | 24.18M | 12.14M | 1.37M | 1.01M |
| shares | — | 94.06M | 80.78M | 58.07M | 51.98M | 38.44M | 30.45M | 24.18M | 12.14M | 1.37M | 1.01M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.68×
EV/EBIT
—
Biotechnology median 26.45×
P/E (TTM)
—
Biotechnology median 7.21×
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Reportable Segment | $7,696,000 | $1,039,000 | $4,013,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Product | $5,420,000 | $0 | $0 |
| License And Service | $2,276,000 | $1,039,000 | $4,013,000 |
Key facts
CIK
1658247
CUSIP
22663K107
13F (30d)
24 filings
23 filers
Visit website
Investor relations